Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122570 | 0.84 | PTGS1 (0.46) | PTGS1SLC7A11ENPEP | |
| SCHEMBL4122573 | 0.84 | PTGS1 (0.46) | PTGS1SLC7A11ENPEP | |
| SCHEMBL24359844 | 0.82 | PTGS1 (0.41) | PTGS1SLC7A11ENPEP | |
| Hydrochloric Acid SCHEMBL8596085 | 0.82 | PTGS1 (0.44) | PTGS1SLC7A11ENPEP | |
| Hydrochloric Acid SCHEMBL9589944 | 0.82 | PTGS1 (0.44) | PTGS1SLC7A11ENPEP | |
| SCHEMBL23408842 | 0.74 | SLC7A5 (0.43) | PTGS1SLC7A11ENPEP | |
| SCHEMBL9384783 | 0.73 | PTGS1 (0.48) | PTGS1SLC7A11ENPEP | |
| SCHEMBL16805828 | 0.72 | TSHR (0.38) | — | |
| SCHEMBL1497690 | 0.72 | PTGS1 (0.48) | PTGS1SLC7A11ENPEP | |
| SCHEMBL28984792 | 0.71 | PTGS1 (0.46) | PTGS1SLC7A11ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | PTGS1 303/4885SLC7A11 2338/4885ENPEP 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.